Pro-Dex (NASDAQ:PDEX) Announces Earnings Results

Pro-Dex (NASDAQ:PDEX) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.23, Zacks reports. Pro-Dex had a net margin of 9.17% and a return on equity of 16.74%.

Pro-Dex Stock Down 0.7 %

Shares of Pro-Dex stock traded down $0.31 on Thursday, hitting $42.95. 31,928 shares of the company’s stock traded hands, compared to its average volume of 28,640. Pro-Dex has a 52-week low of $16.18 and a 52-week high of $59.60. The company has a quick ratio of 1.94, a current ratio of 3.41 and a debt-to-equity ratio of 0.36. The stock has a market cap of $140.02 million, a P/E ratio of 27.89 and a beta of 0.56. The firm’s 50-day moving average is $47.59 and its 200 day moving average is $34.34.

Insider Buying and Selling

In other news, Director Raymond E. Cabillot sold 1,200 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $47.76, for a total transaction of $57,312.00. Following the transaction, the director now owns 359,646 shares of the company’s stock, valued at approximately $17,176,692.96. This trade represents a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Alisha Charlton sold 1,000 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $40.02, for a total value of $40,020.00. Following the completion of the sale, the chief financial officer now directly owns 15,339 shares of the company’s stock, valued at approximately $613,866.78. This represents a 6.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,670 shares of company stock worth $1,229,821. Insiders own 47.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PDEX shares. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th. Ascendiant Capital Markets raised their target price on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.